Plasma tumor DNA: On your markers, get set, go!

Hong Yuen Wong, Ben Ho Park

Research output: Contribution to journalArticle


Metastatic breast cancer is incurable, yet highly treatable with endocrine, HER2 directed and chemotherapies improving survival for many patients. Successful treatment depends on the ability to monitor disease burden and response to therapies. Recently, a proof of principle study has shown that plasma tumor DNA (ptDNA) can be used as a reliable breast cancer biomarker in metastatic disease, due to its sensitivity and wide dynamic range. ptDNA more accurately reflects changes in response to therapies, and absolute levels of ptDNA demonstrate prognostic significance. Thus, ptDNA as a liquid biopsy shows great promise in the clinical management of metastatic breast cancer though further technical challenges and larger confirmatory studies are needed.

Original languageEnglish (US)
Article number2
JournalAnnals of Translational Medicine
Issue number1
StatePublished - Jan 1 2014


  • Circulating tumor DNA (ctDNA)
  • Metastatic breast cancer
  • Plasma biomarker
  • Plasma tumor DNA (ptDNA)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Plasma tumor DNA: On your markers, get set, go!'. Together they form a unique fingerprint.

Cite this